Ross T Campbell

University of Glasgow

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (22)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (8)

Neil Herring

University of Oxford

UNITED KINGDOM

View details

Alasdair David Henderson

University of Glasgow

UNITED KINGDOM

View details

Tor Biering-Sørensen

Professor

University of Copenhagen

DENMARK

View details

Pardeep Jhund

University of Glasgow

UNITED KINGDOM

View details

Alex McConnachie

Professor of Clinical Trial Biostatistics

University of Glasgow

UNITED KINGDOM

View details

Matthew Lee

Clinical Lecturer

University of Glasgow

UNITED KINGDOM

View details

Kieran Docherty

University of Glasgow

UNITED KINGDOM

View details

Thomas Ford

Senior Lecturer

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ross T Campbell

Research Interests

Explore related searches

Contact this professor

Articles (22)

Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure

Pulmonary Congestion on Lung Ultrasound in Ambulatory Patients With Heart Failure With Preserved Ejection Fraction.

What is the Future of Diagnostics in Heart Failure?

Subcutaneous furosemide in heart failure: a systematic review

Predictors of heart failure readmission and all-cause mortality in patients with acute heart failure

Beta‐blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

Simplifying Treatment of Congestion

Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.

Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design.

Reply: subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’

Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction.

Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial.

A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies

Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes.

Calcium channel blocker and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction.

Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction.

Sex differences in congestive markers in patients hospitalized for acute heart failure.

Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction

Urinary peptides in heart failure: a link to molecular pathophysiology.

Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling.

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).

The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure

Collaborators (8)

Neil Herring

Alasdair David Henderson

Tor Biering-Sørensen

Pardeep Jhund

Alex McConnachie

Matthew Lee

Kieran Docherty

Thomas Ford

Make your next move.